Zevra Therapeutics shares are trading higher after Guggenheim initiated coverage on the stock with a Buy rating and announced a price target of $20.
Portfolio Pulse from Benzinga Newsdesk
Zevra Therapeutics shares rose following Guggenheim's initiation of coverage with a Buy rating and a $20 price target.
October 07, 2024 | 6:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Zevra Therapeutics shares increased after Guggenheim initiated coverage with a Buy rating and set a price target of $20, indicating positive analyst sentiment.
The initiation of coverage by a reputable firm like Guggenheim with a Buy rating and a specific price target often leads to increased investor confidence and buying activity, driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100